Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.

Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, Almeida R, Peacock CS, McCann S, Blackwell JM.

Vaccine. 2006 Mar 24;24(14):2602-16. Epub 2005 Dec 20.

PMID:
16406227
2.

The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA, Campos-Neto A, Reed S, Seder RA, Sacks D.

J Immunol. 2001 Apr 15;166(8):5122-8.

3.

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.

Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG.

Vaccine. 2002 Sep 10;20(27-28):3292-303. Erratum in: Vaccine. 2002 Nov 1;20(31-32):3783..

PMID:
12213399
4.

Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Salay G, Dorta ML, Santos NM, Mortara RA, Brodskyn C, Oliveira CI, Barbiéri CL, Rodrigues MM.

Clin Vaccine Immunol. 2007 Sep;14(9):1173-81. Epub 2007 Jul 11.

5.
6.

Expression cloning of a protective Leishmania antigen.

Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, Waldmann R, Locksley RM, Glaichenhaus N.

Science. 1995 Apr 28;268(5210):563-6.

PMID:
7725103
7.

Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.

Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY.

J Immunol. 1999 Aug 1;163(3):1467-72.

8.
9.
10.
11.

DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.

Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C.

Vaccine. 2009 Jan 1;27(1):99-106. doi: 10.1016/j.vaccine.2008.10.013. Epub 2008 Oct 23.

PMID:
18951941
12.

Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.

Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA.

J Exp Med. 2002 Jun 17;195(12):1565-73.

13.

Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.

Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B.

Infect Immun. 2004 Aug;72(8):4521-7.

14.

Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.

Noormohammadi AH, Hochrein H, Curtis JM, Baldwin TM, Handman E.

Vaccine. 2001 Jul 16;19(28-29):4043-52.

PMID:
11427281
15.

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.

Bolhassani A, Gholami E, Zahedifard F, Moradin N, Parsi P, Doustdari F, Seyed N, Papadopoulou B, Rafati S.

Exp Parasitol. 2011 May;128(1):9-17. doi: 10.1016/j.exppara.2011.01.012. Epub 2011 Jan 26.

PMID:
21276444
16.

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.

J Exp Med. 1997 Oct 6;186(7):1137-47.

17.

IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.

Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM.

J Immunol. 2005 Aug 15;175(4):2517-24.

18.

Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains.

Benhnini F, Chenik M, Laouini D, Louzir H, Cazenave PA, Dellagi K.

Clin Vaccine Immunol. 2009 Nov;16(11):1529-37. doi: 10.1128/CVI.00153-09. Epub 2009 Sep 2.

19.
20.

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.

Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.

Exp Parasitol. 2011 Mar;127(3):627-36. doi: 10.1016/j.exppara.2010.12.007. Epub 2010 Dec 25.

PMID:
21187087

Supplemental Content

Support Center